| Year |
Citation |
Score |
| 2017 |
Philipson T, MacEwan JP. The importance of model inputs and assumptions in conducting health technology assessments of novel drugs. Journal of Medical Economics. 1-4. PMID 28737052 DOI: 10.1080/13696998.2017.1359182 |
0.303 |
|
| 2017 |
Philipson TJ, Kamal-Bahl S, Jena AB. Defining Value: The Need for a Longer, Broader View. Pharmacoeconomics. PMID 28337720 DOI: 10.1007/S40273-017-0503-7 |
0.415 |
|
| 2016 |
Basu A, Axelsen K, Grabowski DC, Meltzer DO, Polsky D, Ridley DB, Wiederkehr D, Philipson TJ. Real-World Data: Responses to Zito and Doshi. Medical Care. PMID 27676401 DOI: 10.1097/MLR.0000000000000655 |
0.373 |
|
| 2016 |
Basu A, Axelsen K, Grabowski DC, Meltzer DO, Polsky D, Ridley DB, Wiederkehr D, Philipson TJ. Real World Data: Policy Issues Regarding their Access and Use. Medical Care. PMID 27489028 DOI: 10.1097/MLR.0000000000000603 |
0.486 |
|
| 2016 |
Jena AB, Stevens W, Gonzalez YS, Marx SE, Juday T, Lakdawalla DN, Philipson TJ. The wider public health value of HCV treatment accrued by liver transplant recipients. The American Journal of Managed Care. 22: SP212-9. PMID 27266951 |
0.396 |
|
| 2014 |
Stevens W, Philipson T, Wu Y, Chen C, Lakdawalla D. A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies. Forum For Health Economics & Policy. 17: 21-52. PMID 31419878 DOI: 10.1515/Fhep-2013-0025 |
0.349 |
|
| 2014 |
Goldman DP, Philipson T. Five myths about cancer care in America. Health Affairs (Project Hope). 33: 1801-4. PMID 25288425 DOI: 10.1377/Hlthaff.2014.0826 |
0.332 |
|
| 2014 |
Philipson T, Linthicum MT, Snider JT. Tutorial on health economics and outcomes research in nutrition. Jpen. Journal of Parenteral and Enteral Nutrition. 38: 5S-16S. PMID 25239114 DOI: 10.1177/0148607114549770 |
0.379 |
|
| 2014 |
de van der Schueren M, Elia M, Gramlich L, Johnson MP, Lim SL, Philipson T, Jaferi A, Prado CM. Clinical and economic outcomes of nutrition interventions across the continuum of care. Annals of the New York Academy of Sciences. 1321: 20-40. PMID 25123208 DOI: 10.1111/Nyas.12498 |
0.347 |
|
| 2014 |
Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Response to Epstein's comment on "heterogeneity in action". Health Economics. 23: 376-8. PMID 24446313 DOI: 10.1002/Hec.3031 |
0.38 |
|
| 2014 |
Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Heterogeneity in action: the role of passive personalization in comparative effectiveness research. Health Economics. 23: 359-73. PMID 24123568 DOI: 10.1002/Hec.2996 |
0.46 |
|
| 2014 |
Philipson TJ, Zanjani G. Economic analysis of risk and uncertainty induced by health shocks: A review and extension Handbook of the Economics of Risk and Uncertainty. 1: 453-491. DOI: 10.1016/B978-0-444-53685-3.00008-8 |
0.377 |
|
| 2013 |
Goldman DP, Gupta C, Vasudeva E, Trakas K, Riley R, Lakdawalla D, Agus D, Sood N, Jena AB, Philipson TJ. The Value of Diagnostic Testing in Personalized Medicine. Forum For Health Economics & Policy. 16: S87-S99. PMID 31419871 DOI: 10.1515/Fhep-2013-0023 |
0.469 |
|
| 2013 |
Jena AB, Mechoulan S, Philipson TJ. Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases. Forum For Health Economics & Policy. 16: 83-99. PMID 31419863 DOI: 10.1515/Fhep-2012-0036 |
0.473 |
|
| 2013 |
Jena AB, Philipson TJ. Endogenous cost-effectiveness analysis and health care technology adoption. Journal of Health Economics. 32: 172-80. PMID 23202262 DOI: 10.1016/J.Jhealeco.2012.10.002 |
0.518 |
|
| 2013 |
Stomberg C, Philipson T, Albaugh M, Sood N. Utilization effects of Rx-OTC switches and implications for future switches Health. 5: 1667-1680. DOI: 10.4236/Health.2013.510225 |
0.308 |
|
| 2012 |
Philipson TJ, Sun E, Goldman D, Jena AB. A Reexamination of the Costs of Medical R&D Regulation. Forum For Health Economics & Policy. 15: 1-28. PMID 31419852 DOI: 10.1515/Fhep-2012-0020 |
0.499 |
|
| 2012 |
Grabowski DC, Lakdawalla DN, Goldman DP, Eber M, Liu LZ, Abdelgawad T, Kuznik A, Chernew ME, Philipson T. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Affairs (Project Hope). 31: 2276-85. PMID 23048109 DOI: 10.1377/Hlthaff.2011.1120 |
0.525 |
|
| 2012 |
Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Affairs (Project Hope). 31: 676-82. PMID 22492883 DOI: 10.1377/Hlthaff.2011.1300 |
0.322 |
|
| 2012 |
Philipson T, Eber M, Lakdawalla DN, Corral M, Conti R, Goldman DP. An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. Health Affairs (Project Hope). 31: 667-75. PMID 22492882 DOI: 10.1377/Hlthaff.2011.1298 |
0.333 |
|
| 2012 |
Malani A, Philipson TJ. The Regulation of Medical Products The Oxford Handbook of the Economics of the Biopharmaceutical Industry. DOI: 10.1093/oxfordhb/9780199742998.013.0005 |
0.729 |
|
| 2012 |
Lakdawalla D, Goldman D, Philipson T. PIH24 Modeling the Health and Medical Care Spending of the Future Elderly: An Update Using the Future Elderly Model Value in Health. 15: A195-A196. DOI: 10.1016/J.Jval.2012.03.1056 |
0.315 |
|
| 2011 |
Basu A, Jena AB, Philipson TJ. The impact of comparative effectiveness research on health and health care spending. Journal of Health Economics. 30: 695-706. PMID 21696840 DOI: 10.1016/J.Jhealeco.2011.05.012 |
0.497 |
|
| 2011 |
Goldman DP, Lakdawalla DN, Malkin JD, Romley J, Philipson T. The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data. Health Affairs (Project Hope). 30: 84-90. PMID 21209443 DOI: 10.1377/Hlthaff.2009.1056 |
0.312 |
|
| 2011 |
Jena A, Philipson T. PHP168 Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption Value in Health. 14: A363-A364. DOI: 10.1016/J.Jval.2011.08.718 |
0.488 |
|
| 2011 |
Philipson T. PHP18 OPTIMAL HEALTH POLICY AND THE LINK BETWEEN OUTPUT MARKETS AND DEVELOPMENT Value in Health. 14: A15. DOI: 10.1016/J.Jval.2011.02.091 |
0.302 |
|
| 2010 |
Goldman D, Lakdawalla D, Philipson TJ, Yin W. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. Health Economics. 19: 1109-16. PMID 20842680 DOI: 10.1002/Hec.1654 |
0.363 |
|
| 2010 |
Lakdawalla DN, Sun EC, Jena AB, Reyes CM, Goldman DP, Philipson TJ. An economic evaluation of the war on cancer. Journal of Health Economics. 29: 333-46. PMID 20363520 DOI: 10.1016/J.Jhealeco.2010.02.006 |
0.5 |
|
| 2010 |
Sun E, Jena AB, Lakdawalla D, Reyes C, Philipson TJ, Goldman D. The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 Forum For Health Economics & Policy. 13. DOI: 10.2202/1558-9544.1195 |
0.423 |
|
| 2010 |
Philipson T, Becker GS, Goldman DP, Murphy KM. Terminal Care and the Value of Life Near its End National Bureau of Economic Research. DOI: 10.2139/Ssrn.1544510 |
0.626 |
|
| 2010 |
Jena AB, Mechoulan S, Philipson TJ. Altruism and innovation in health care Journal of Law and Economics. 53: 497-518. DOI: 10.1086/648383 |
0.511 |
|
| 2009 |
Jena AB, Calfee JE, Mansley EC, Philipson TJ. 'Me-Too' Innovation in Pharmaceutical Markets. Forum For Health Economics & Policy. 12. PMID 29081727 DOI: 10.2202/1558-9544.1138 |
0.515 |
|
| 2008 |
Sun E, Lakdawalla D, Reyes C, Goldman D, Philipson T, Jena A. The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6616. PMID 27949685 DOI: 10.1200/Jco.2008.26.15_Suppl.6616 |
0.43 |
|
| 2008 |
Jena AB, Philipson TJ. Cost-effectiveness analysis and innovation. Journal of Health Economics. 27: 1224-36. PMID 18619695 DOI: 10.1016/J.Jhealeco.2008.05.010 |
0.504 |
|
| 2008 |
Goldman DP, Jena AB, Philipson T, Sun E. Drug licenses: a new model for pharmaceutical pricing. Health Affairs (Project Hope). 27: 122-9. PMID 18180487 DOI: 10.1377/Hlthaff.27.1.122 |
0.532 |
|
| 2008 |
Jena AB, Mulligan CB, Philipson T, Sun EC. The Value of Life in General Equilibrium National Bureau of Economic Research. DOI: 10.3386/W14157 |
0.533 |
|
| 2008 |
Philipson T, Posner RA. Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity National Bureau of Economic Research. DOI: 10.3386/W14010 |
0.303 |
|
| 2008 |
Sun E, Lakdawalla D, Reyes C, Goldman D, Philipson T, Jena A. PCN92 THE WAR ON CANCER: AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL Value in Health. 11: A82. DOI: 10.1016/S1098-3015(10)70268-0 |
0.479 |
|
| 2008 |
Philipson T, Berndt ER, Gottschalk AHB, Sun E. Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts Journal of Public Economics. 92: 1306-1325. DOI: 10.1016/J.Jpubeco.2007.09.010 |
0.36 |
|
| 2007 |
Goldman D, Philipson TJ. Integrated Insurance Design in the Presence of Multiple Medical Technologies. The American Economic Review. 97: 427-432. PMID 30983595 DOI: 10.1257/Aer.97.2.427 |
0.328 |
|
| 2007 |
Jena AB, Philipson T. Cost-effectiveness as a price control. Health Affairs (Project Hope). 26: 696-703. PMID 17485746 DOI: 10.1377/Hlthaff.26.3.696 |
0.492 |
|
| 2007 |
Philipson T, Jena AB, Sun E. The Institute of Medicine report on the FDA: where is the science? Health Economics. 16: 219-21. PMID 17315264 DOI: 10.1002/Hec.1222 |
0.466 |
|
| 2007 |
Becker GS, Murphy KM, Philipson T. The Value of Life Near its End and Terminal Care National Bureau of Economic Research. DOI: 10.3386/W13333 |
0.625 |
|
| 2007 |
Jena AB, Philipson TJ. CEA: The authors respond [3] Health Affairs. 26: 1506-1507. DOI: 10.1377/Hlthaff.26.5.1506 |
0.384 |
|
| 2006 |
Philipson TJ, Jena AB. Striking a balance on new technology. Cost-effectiveness analysis can help sort out emerging health care technologies, but what are the consequences for continued medical innovation? Ahip Coverage. 47: 29, 31, 33. PMID 17007325 |
0.489 |
|
| 2006 |
Philipson T, Mechoulan S, Jena AB. Health Care, Technological Change, and Altruistic Consumption Externalities National Bureau of Economic Research. DOI: 10.3386/W11930 |
0.536 |
|
| 2006 |
Philipson TJ, Jena AB. Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs Forum For Health Economics & Policy. 9. DOI: 10.2202/1558-9544.1005 |
0.491 |
|
| 2005 |
Becker GS, Philipson TJ, Soares RR. The Quantity and Quality of Life and the Evolution of World Inequality. The American Economic Review. 95: 277-91. PMID 29120118 DOI: 10.1257/0002828053828563 |
0.568 |
|
| 2005 |
Becker GS, Philipson TJ, Soares RR. The quantity and quality of life and the evolution of world inequality American Economic Review. 95: 277-291. DOI: 10.1257/0002828053828563 |
0.518 |
|
| 2002 |
Lakdawalla D, Philipson T. The Rise in Old-Age Longevity and the Market for Long-Term Care. The American Economic Review. 92: 295-306. PMID 29058393 DOI: 10.1257/000282802760015739 |
0.31 |
|
| 2002 |
Geoffard P, Philipson T. Pricing and R&D When Consumption Affects Longevity The Rand Journal of Economics. 33: 85. DOI: 10.2307/2696376 |
0.326 |
|
| 1999 |
Lakdawalla DN, Philipson T. Aging and the Growth of Long-Term Care National Bureau of Economic Research. DOI: 10.3386/W6980 |
0.316 |
|
| 1999 |
Cawley J, Philipson T. An empirical examination of information barriers to trade in insurance American Economic Review. 89: 827-846. DOI: 10.1257/Aer.89.4.827 |
0.349 |
|
| 1999 |
Philipson T, Malani A. Measurement errors: A principal investigator-agent approach Journal of Econometrics. 91: 273-298. DOI: 10.1016/S0304-4076(98)00078-5 |
0.711 |
|
| 1998 |
Lakdawalla DN, Philipson T. Nonprofit Production and Competition National Bureau of Economic Research. DOI: 10.3386/W6377 |
0.346 |
|
| 1998 |
Philipson TJ, Becker GS. Old-Age Longevity and Mortality-Contingent Claims Journal of Political Economy. 106: 551-573. DOI: 10.1086/250021 |
0.558 |
|
| 1997 |
Mullin C, Philipson T. The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims National Bureau of Economic Research. DOI: 10.3386/W6042 |
0.321 |
|
| 1997 |
Philipson T. Data Markets and the Production of Surveys Review of Economic Studies. 64: 47-72. DOI: 10.2307/2971740 |
0.318 |
|
| 1997 |
Philipson T, Lawless T. Multiple-output agency incentives in data production: Experimental evidence European Economic Review. 41: 961-970. DOI: 10.1016/S0014-2921(97)00054-8 |
0.313 |
|
| 1997 |
Philipson T. The evaluation of new health care technology: The labor economics of statistics Journal of Econometrics. 76: 375-395. DOI: 10.1016/0304-4076(95)01798-4 |
0.364 |
|
| 1996 |
Philipson T, Becker GS. Mortality Contingent Claims, Health Care, and Social Insurance National Bureau of Economic Research. DOI: 10.3386/W5760 |
0.605 |
|
| 1995 |
Dow WH, Holmes J, Philipson T, Sala-i-Martin X. Disease Complementarities and the Evaluation of Public Health Interventions National Bureau of Economic Research. DOI: 10.3386/W5216 |
0.331 |
|
| 1993 |
Philipson T. Social Welfare and Measurement of Segregation Journal of Economic Theory. 60: 322-334. DOI: 10.1006/Jeth.1993.1046 |
0.302 |
|
| 1992 |
Heckman JJ, Philipson TJ. Evaluating an Argument for Affirmative Action Rationality and Society. 4: 360-364. DOI: 10.1177/1043463192004003008 |
0.363 |
|
| Show low-probability matches. |